Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin and Lupin Pharmaceuticals have resolved its patent dispute related to Lunesta (Eszopicolone) tablets with Dainippon Sumitomo Pharma, which follows the dismissing of a patent suit brought by Sunovion Pharmaceuticals, a subsidiary of Dainippon Sumitomo.
Subscribe to our email newsletter
Lunesta, a sedative, also called a hypnotic, is used to treat insomnia and causes relaxation to help you fall asleep and stay asleep.
The suit settlement allows Lupin to sell its generic version of Lunesta under a license as soon as 30 November 2013.
Lupin is a led transnational pharmaceutical company that produces a range of generic and branded formulations and APIs for the developed and developing markets of the world.